{
    "clinical_study": {
        "@rank": "10065", 
        "arm_group": [
            {
                "arm_group_label": "Group 1: Dapagliflozin", 
                "arm_group_type": "Experimental", 
                "description": "Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin"
            }, 
            {
                "arm_group_label": "Group 2: Dapagliflozin Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose is to determine if after  24 weeks of oral daily administration, there will be a\n      greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) achieved with\n      Dapagliflozin 10 mg plus insulin compared to placebo plus insulin in subjects with type 2\n      diabetes."
        }, 
        "brief_title": "Phase III Insulin Add-On Asia Regional Program - ST", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com.\n\n        Inclusion Criteria:\n\n          -  Subjects must have type 2 diabetes with inadequate glycemic control, defined as HbA1c\n             \u2265 7.5% and \u2264 11.0% obtained at screening visit\n\n          -  Subjects must be taking a stable mean dose of \u2265 20 IU injectable insulin daily for at\n             least 8 weeks prior to enrollment\n\n          -  Fasting C-peptide \u2265 1.0 ng/mL (0.34nmol/L) at enrollment visit\n\n        Exclusion Criteria:\n\n          -  Treatment with more than two oral antidiabetic (OAD) agents within 6 weeks of\n             Enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "260", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096705", 
            "org_study_id": "MB102-137"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1: Dapagliflozin", 
                "intervention_name": "Dapagliflozin", 
                "intervention_type": "Drug", 
                "other_name": "BMS-512148"
            }, 
            {
                "arm_group_label": "Group 2: Dapagliflozin Placebo", 
                "intervention_name": "Dapagliflozin Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 3, 2014", 
        "number_of_arms": "2", 
        "official_title": "A 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate Efficacy and Safety of Dapagliflozin Added to Therapy of Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "Korea: Food and Drug Administration", 
                "Singapore: Clinical Trials & Epidemiology Research Unit (CTERU)", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in HbA1c at Week 24", 
            "safety_issue": "No", 
            "time_frame": "Baseline (Day 1) and 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096705"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in Fasting plasma glucose (FPG) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) and 24 weeks"
            }, 
            {
                "measure": "Change from baseline in Body weight at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) and 24 weeks"
            }, 
            {
                "measure": "Change from baseline in Absolute calculated mean total daily dose of insulin (TDDI) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1) and 24 weeks"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}